Wang Qing-Dong, Sjöquist Per-Ove
Integrative Pharmacology, AstraZeneca R&D Mölndal, Mölndal 431 83, Sweden.
Pharmacol Res. 2006 Apr;53(4):331-40. doi: 10.1016/j.phrs.2006.01.009. Epub 2006 Feb 28.
Cell therapy through the application of stem or progenitor cells to regenerate and repair damaged myocardium has gone from the bench to clinical trial. The functional benefits observed in clinical trials are, however, moderate, and many challenges need to be overcome before cell therapy can be put into widespread clinical use. Better understanding of the signals and molecules that promote cell proliferation, differentiation, engraftment and survival may lead to development of pharmacological agents that enhance the capacity of stem/progenitor cells for myocardial regeneration. The present review will provide a critical analysis of the merits and limitations of different populations of stem/progenitor cells and discuss the potential of pharmacological strategies for enhancing the efficacy of cell therapy for myocardial regeneration.
通过应用干细胞或祖细胞来再生和修复受损心肌的细胞疗法已从实验室走向临床试验。然而，在临床试验中观察到的功能益处是适度的，并且在细胞疗法能够广泛应用于临床之前，还有许多挑战需要克服。更好地了解促进细胞增殖、分化、植入和存活的信号和分子，可能会导致开发出增强干细胞/祖细胞心肌再生能力的药物。本综述将对不同类型的干细胞/祖细胞的优缺点进行批判性分析，并讨论增强心肌再生细胞疗法疗效的药理学策略的潜力。
